Programmed Cell Death-Ligand 1 (PD-L1) Immunohistochemical Expression in Equine Melanocytic Tumors.

Summary

# Editorial Summary: PD-L1 Expression in Equine Melanomas—A Gateway to Immunotherapy? Equine melanocytic tumours present a frustrating clinical challenge: traditional interventions are hampered by tumour location, size, and metastatic spread, leaving practitioners with limited options for cases beyond surgical reach. This 2023 study examined whether PD-L1 (programmed cell death-ligand 1)—a protein that helps tumours evade the immune system—might serve as a therapeutic target, following promising results with PD-1/PD-L1 blockade in human melanoma treatment. Researchers evaluated immunohistochemical PD-L1 expression across 77 equine melanocytic tumours (38 malignant, 39 benign), quantifying the proportion of labelled cells in each sample. Nearly 60% of all tumours showed strong PD-L1 expression (>50% of cells), with malignant tumours demonstrating particularly robust expression: 63% exhibited >50% labelling, whilst only one lacked meaningful expression. Benign tumours displayed more variable expression patterns, though 56% still showed >50% labelling, suggesting PD-L1 blockade could become a viable immunotherapeutic avenue for horses with advanced or inoperable melanomas—warranting urgent progression to clinical efficacy trials.

Read the full abstract on PubMed

Key Findings

• •59.7% of equine melanocytic tumors showed >50% PD-L1 immunolabeled cells
• •63.2% of malignant melanocytic tumors (24/38) presented >50% PD-L1 expression
• •56.4% of benign melanocytic tumors (22/39) presented >50% PD-L1 expression
• •PD-L1 blockade may represent a potential immunotherapeutic target for equine melanocytic tumors

Conditions Studied

Tags